21 Ha’arba’a Street
337 articles with RedHill Biopharma
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has submitted Clinical Trial Applications (CTA) with the UK Medicines & Healthcare Products Regulatory Agency (MHRA) and the Italian Medicines Agency (AIFA) for a Phase 2/3 clinical study evaluating opaganib (Yeliva®, ABC294640)
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 patients is being initiated in the U.S. TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a s
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
RedHill Biopharma Ltd. announced that Mr. Gilead Raday, RedHill’s Chief Operating Officer, will present the Company’s development program with opaganib 1 for COVID-19, as well as the Phase 3 development program with RHB-204 for pulmonary nontuberculous mycobacteria infections, at the MedInvest Virtual Infectious Diseases and Immunology Conference on Monday, June 15, 2020, at 12:40 p.m. EDT.
RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Adi Frish, RedHill’s Senior Vice President Business Development and Licensing, will present a corporate overview at BIO Digital, taking place June 8-12, 2020. The presentation will be available during the conference on-demand via https://www.bio.org/events/bio-digital/sessions/658958
RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020, at 11:00 a.m. EDT . The presentation will be broadcast live and available via replay for 30 days on the Company's website, htt
RedHill Biopharma Provides Q1/2020 Financial Results and Recent Highlights Including Initial Movantik® Revenues
Completed acquisition of Movantik® from AstraZeneca on April 1, 2020, and initiated U.S. promotion with net revenues of $7.3 million in April
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will report its first quarter 2020 financial results on Wednesday, May 27, 2020.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the UBS Virtual Global Healthcare Conference on Monday, May 18, 2020, at 7:30 a.m. EDT.
5/11/2020It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged from the hospital -- Opaganib’s unique mechanism of action has both anti-inflammatory and anti-viral activities, targeting a critical host factor, minimizing potential development of resistance du
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
5/7/2020Pharma and life sciences companies from across the globe provide updates on their business and pipelines.
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week® (DDW) 2020
RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies
Six COVID-19 Patients Treated with RedHill’s Opaganib Under Compassionate Use Show Objective Clinical Improvement
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19RedHill is pursuing both RHB-107 and opaganib as potential treatments for COVID-19
RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide its investigational drug, RHB-107 (upamostat, WX-671) 1 , for testing in non-clinical studies for activity against SARS-CoV-2,
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
Objective improvement in first two patients treated with opaganib in Israel who have demonstrated measurable clinical improvement within days of treatment initiation, including decreased supplemental oxygen requirements, decreased C-reactive protein (CRP) levels and increased lymphocyte levels -- One patient was treated in the ICU, was considered for intubation, and was released within days of treatment-initiation -- Opaganib was administered in addition to standard-of-care, including hy
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use
Compassionate use approved by Israeli Ministry of Health; Additional patients expected to be treated in the coming days